Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,640,526
  • Shares Outstanding, K 158,759
  • Annual Sales, $ 329,000 K
  • Annual Income, $ 23,380 K
  • EBIT $ 103 M
  • EBITDA $ 98 M
  • 60-Month Beta 1.85
  • Price/Sales 8.88
  • Price/Cash Flow 237.57
  • Price/Book 7.45

Options Overview Details

View History
  • Implied Volatility 74.84% (+3.50%)
  • Historical Volatility 40.62%
  • IV Percentile 76%
  • IV Rank 48.32%
  • IV High 111.36% on 07/10/25
  • IV Low 40.70% on 01/21/26
  • Expected Move (DTE 1) 0.94 (3.20%)
  • Put/Call Vol Ratio 0.66
  • Today's Volume 794
  • Volume Avg (30-Day) 1,411
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 66,960
  • Open Int (30-Day) 62,545
  • Expected Range 28.30 to 30.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.35
  • Number of Estimates 5
  • High Estimate 0.43
  • Low Estimate 0.27
  • Prior Year 0.15
  • Growth Rate Est. (year over year) +133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.60 +5.89%
on 02/05/26
32.55 -10.20%
on 01/23/26
-1.34 (-4.38%)
since 01/16/26
3-Month
26.89 +8.70%
on 01/13/26
33.78 -13.48%
on 11/26/25
-1.98 (-6.34%)
since 11/18/25
52-Week
25.28 +15.62%
on 08/11/25
46.48 -37.11%
on 05/01/25
-1.93 (-6.19%)
since 02/18/25

Most Recent Stories

More News
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent...

TGTX : 29.23 (+0.58%)
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration...

TGTX : 29.23 (+0.58%)
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ®  (ublituximab-xiiy), to be presented at the Americas...

TGTX : 29.23 (+0.58%)
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ®  (ublituximab-xiiy), to be presented...

TGTX : 29.23 (+0.58%)
Stock Indexes Settle Lower on Tech Weakness

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.07%. March...

MSTR : 125.20 (-2.70%)
GOOGL : 303.33 (+0.43%)
MPC : 199.57 (-0.48%)
GLXY : 21.73 (+2.02%)
RIVN : 16.15 (-1.94%)
ABNB : 124.27 (+0.03%)
COIN : 164.05 (-1.19%)
TGTX : 29.23 (+0.58%)
OXY : 47.11 (+2.55%)
TSLA : 411.32 (+0.17%)
^BTCUSD : 66,466.70 (+0.15%)
SPY : 686.29 (+0.50%)
Stocks Retreat as Big Tech Falters

The S&P 500 Index ($SPX ) (SPY ) today is down -0.96%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. March E-mini S&P futures...

MSTR : 125.20 (-2.70%)
GOOGL : 303.33 (+0.43%)
MPC : 199.57 (-0.48%)
GLXY : 21.73 (+2.02%)
RIVN : 16.15 (-1.94%)
COIN : 164.05 (-1.19%)
TGTX : 29.23 (+0.58%)
OXY : 47.11 (+2.55%)
TSLA : 411.32 (+0.17%)
^BTCUSD : 66,466.70 (+0.15%)
SPY : 686.29 (+0.50%)
META : 643.22 (+0.61%)
Stocks Pressured by Tech Weakness and Iran Tensions

The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.22%. March E-mini S&P futures...

AMAT : 369.30 (+2.83%)
GOOGL : 303.33 (+0.43%)
MPC : 199.57 (-0.48%)
AVGO : 333.51 (+0.29%)
CVX : 183.87 (+1.84%)
FN : 505.78 (+1.81%)
RIVN : 16.15 (-1.94%)
$IUXX : 24,898.87 (+0.80%)
ZNH26 : 112-265 (-0.11%)
MSFT : 399.60 (+0.69%)
TGTX : 29.23 (+0.58%)
OXY : 47.11 (+2.55%)
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594...

TGTX : 29.23 (+0.58%)
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 44 th...

TGTX : 29.23 (+0.58%)
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8...

TGTX : 29.23 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 30.11
2nd Resistance Point 29.68
1st Resistance Point 29.45
Last Price 29.23
1st Support Level 28.79
2nd Support Level 28.36
3rd Support Level 28.13

See More

52-Week High 46.48
Fibonacci 61.8% 38.38
Fibonacci 50% 35.88
Fibonacci 38.2% 33.38
Last Price 29.23
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar